Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit-Reference-Cited by-同舟云学术

Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit

Published:2024-03-06 Issue:1 Volume:4 Page:
ISSN:2770-3533
Container-title:International Journal of Cancer Care and Delivery
language:en
Short-container-title:

Author:

Khan Abdul Moiz¹^ORCID,Abuali Inas²,Abrams Hannah³^ORCID,Riano Ivy⁴,Larkin Karilyn T⁵,Wieduwilt Matthew⁶,Nowakowski Grzegorz S⁷,Kumar Shaji⁷

Affiliation:

1. Karmanos Cancer Institute, Detroit, MI, USA

2. Massachusetts General Hospital, Boston, MA, USA

3. Fred Hutch Cancer Center, Seattle, WA, USA

4. Dartmouth–Hitchcock Medical Center, Lebanon, NH, USA

5. The Ohio State University, Columbus, OH, USA

6. Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA

7. Mayo Clinic, Rochester, MN, USA

Abstract

The 2023 Precision Oncology Summit was organized by Binaytara foundation in San Francisco on October 7th and 8th. The conference’s theme was the advances in precision oncology and future directions to move away from a one-size-fits-all model to improve outcomes. This manuscript outlines the proceedings of the hematology-focused session during the conference.

Publisher

Binaytara Foundation

Reference33 articles.

1. Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial;Jorge E. Cortes;Blood,2022

2. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes;Pierre Fenaux;New England Journal of Medicine,2020

3. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial;Uwe Platzbecker;The Lancet,2023

4. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial;Animesh Pardanani;JAMA Oncology,2015

5. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study;Claire N Harrison;The Lancet Haematology,2017